Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
You may also be interested in...
The company said it was optimistic about settling opioid litigation while still anticipating going to trial on price fixing.
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.